InsidersTradesSigma
Total declarations
Company
▲ Purchases (12 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
12
Disclosed sells
0
T+90 hit rate
25%
T+90 mean return
-23.0%
Across 8 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by Lin Patrick, Directeur Stratégie. Insider active across 1 company, notably Processa Pharmaceuticals, Inc.. Aggregated, 21 reports have been logged. Breakdown: 12 buys · 0 sell. Total volume traded: €123k. Activity tracked since 21 June 2021. The latest transaction was filed on 30 April 2026 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Lin Patrick
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations21 total
1,511 shares@ US$2.690.068% mcap1.8% of flowCommon StockSEC:0000897069-26-001004:0
Canonical exit: 29 Jul 2026 (T+90)
1,369 shares@ US$2.970.068% mcap1.7% of flowCommon StockSEC:0000897069-26-000908:0
Canonical exit: 14 Jul 2026 (T+90)
1,603 shares@ US$2.5352.6% of flowCommon StockSEC:0000897069-26-000747:0
Canonical exit: 29 Jun 2026 (T+90)
193 shares0Common StockSEC:0000897069-26-000222:0
14,482 sharesCommon StockSEC:0000897069-25-000795:0
43,500 shares@ US$0.797517.1% of flowCommon StockSEC:0000897069-25-000130:0
Canonical exit: 27 Apr 2025 (T+90)
1,675 sharesCommon StockSEC:0000897069-24-001611:0
1,675 sharesCommon StockSEC:0000897069-24-000921:0
2,500 shares@ US$2.372.8% of flowCommon StockSEC:0000897069-24-000236:0
Canonical exit: 30 Apr 2024 (T+90)
5,000 shares@ US$0.320.8% of flowCommon StockSEC:0000897069-23-001466:0
13,700 shares@ US$0.211.4% of flowCommon StockSEC:0000897069-23-001442:0
12,500 shares@ US$0.804.8% of flowCommon StockSEC:0001567619-23-002400:0
7,601 sharesCommon StockSEC:0001567619-22-015301:0
2,000 shares@ US$1.59452.4% of flowCommon StockSEC:0001567619-22-011300:0
Canonical exit: 15 Aug 2022 (T+90)
1,200 shares@ US$3.12672.7% of flowCommon StockSEC:0001567619-22-008312:0
Canonical exit: 5 Jul 2022 (T+90)
3,000 shares@ US$4.000.16% mcap7.5% of flowCommon StockSEC:0001567619-22-000291:0
Canonical exit: 14 Mar 2022 (T+90)
3,000 shares@ US$4.008.4% of flowCommon StockSEC:0001567619-21-022195:0
Canonical exit: 14 Mar 2022 (T+90)
3,500 shares@ US$4.798611.8% of flowCommon StockSEC:0001567619-21-021708:0
Canonical exit: 3 Mar 2022 (T+90)
4,000 shares@ US$6.02216.2% of flowCommon StockSEC:0001567619-21-016470:0
Canonical exit: 24 Nov 2021 (T+90)
7,601 sharesCommon StockSEC:0001567619-21-014747:0
2,000 shares@ US$6.658.8% of flowCommon StockSEC:0001567619-21-012486:0
Canonical exit: 19 Sept 2021 (T+90)
21 of 21 declarations
About Lin Patrick
Lin Patrick is Directeur Stratégie at Processa Pharmaceuticals, Inc. (XNAS). The 21 filings recorded are acquisitions, with buys in the sampled recent filings from 2021-06-22 to 2026-05-01 totaling EUR 123266 and no sales.
